FDA 510(k) vs EU MDR: what is the difference for medical devices?
FDA 510(k) is a US premarket pathway that clears a device by showing it is substantially equivalent to a legally marketed predicate, while EU MDR (Regulation 2017/745) requires CE marking through a risk-based class (I, IIa, IIb, III) with most classes needing a Notified Body conformity assessment. ISO 13485 quality management underpins both, and the FDA QMSR now aligns US requirements with ISO 13485.
A medical device sold in the United States and one sold in the European Union must clear different regulatory systems. The US uses FDA premarket pathways based largely on equivalence and risk, while the EU uses CE marking under the Medical Device Regulation with conformity assessed by class. Knowing which pathway applies determines the evidence, the timeline, and who reviews the device.
US FDA premarket pathways
In the US, most moderate-risk (Class II) devices use the 510(k) pathway, which requires demonstrating substantial equivalence to a legally marketed predicate device. Higher-risk (Class III) devices generally require Premarket Approval (PMA) with clinical evidence. Novel low-to-moderate-risk devices with no suitable predicate can use the De Novo classification request to create a new device type.
EU MDR pathway
Under EU MDR (Regulation 2017/745), devices are placed in classes I, IIa, IIb, or III by risk. The manufacturer affixes the CE mark after a conformity assessment, which for most classes above self-certified Class I requires a Notified Body to review technical documentation and the quality system. Class III and implantable devices face the most scrutiny.
| Aspect | US FDA | EU MDR (2017/745) |
|---|---|---|
| Legal basis | FD&C Act, 21 CFR | Regulation (EU) 2017/745 |
| Risk tiers | Class I / II / III | Class I / IIa / IIb / III |
| Main pathways | 510(k), De Novo, PMA | CE marking by class |
| Core test | Substantial equivalence (510(k)) or safety/effectiveness (PMA) | Conformity with MDR requirements |
| Independent reviewer | FDA | Notified Body (most classes) |
| Market authorization | 510(k) clearance / De Novo grant / PMA approval | CE mark + EU Declaration of Conformity |
| Quality system | QMSR (aligned to ISO 13485) | ISO 13485 in practice |
What both have in common
- ·ISO 13485 quality management is the practical backbone of both systems.
- ·The FDA Quality Management System Regulation (QMSR) aligns US quality requirements with ISO 13485.
- ·Both require risk management (commonly per ISO 14971) and documented technical evidence.
- ·A device cleared or approved in one market is not automatically authorized in the other.
How MPBxChange handles it
On MPBxChange, medical-device sourcing is matched on specification, so a request can carry the destination market, the device class, and the required pathway (510(k), De Novo, PMA, or CE marking under MDR) as part of the spec shape. Counterparty identity stays sealed during matching. Where a deal uses milestone escrow, release can be tied to conformity evidence such as a 510(k) clearance number, an EU Declaration of Conformity and CE certificate, Notified Body identification, and ISO 13485 status, so each party is matched on the regulatory evidence the destination market actually requires.
Frequently asked questions
No. A 510(k) clearance authorizes US marketing only. To sell in the EU you need CE marking under MDR, which for most device classes requires a Notified Body conformity assessment and an EU Declaration of Conformity.
PMA is generally required for high-risk Class III devices that support or sustain life or present significant injury risk, where substantial equivalence to a predicate is not appropriate. PMA requires its own safety and effectiveness evidence, often including clinical data.
The FDA Quality Management System Regulation (QMSR) aligns US device quality requirements with ISO 13485, reducing the gap between US and international quality expectations, though market authorization pathways remain separate.